{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T14:48:03Z","timestamp":1782139683251,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.euf.2022.02.004","type":"journal-article","created":{"date-parts":[[2022,2,19]],"date-time":"2022-02-19T07:37:43Z","timestamp":1645256263000},"page":"1696-1702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors"],"prefix":"10.1016","volume":"8","author":[{"given":"Matteo","family":"Santoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Bracarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc R.","family":"Matrana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimma","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"De Giorgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaetano","family":"Aurilio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Incorvaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Martignetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Molina-Cerrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Mollica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Battelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2022.02.004_b0005","unstructured":"American Cancer Society. http:\/\/www.cancer.org\/research\/cancerfactsstatistics\/cancerfactsfigures2020."},{"key":"10.1016\/j.euf.2022.02.004_b0010","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1016\/j.clgc.2020.10.008","article-title":"Artificial neural networks as a way to predict future kidney cancer incidence in the United States","volume":"19","author":"Santoni","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euf.2022.02.004_b0015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs\u2014part A: renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2022.02.004_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2021.03.001","article-title":"Impact of clinicopathological features on survival in patients treated with first-line immune checkpoint inhibitors plus tyrosine kinase inhibitors for renal cell carcinoma: a meta-analysis of randomized clinical trials","author":"Rizzo","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2022.02.004_b0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1080\/14737167.2021.1937130","article-title":"Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis","volume":"22","author":"Santoni","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.euf.2022.02.004_b0030","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ejca.2021.06.015","article-title":"Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomized clinical trials","volume":"154","author":"Massari","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euf.2022.02.004_b0035","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.2217\/fon-2021-0069","article-title":"Quality of life assessment in RCC phase II and III clinical trials published between 2010 and 2020: a systematic review","volume":"17","author":"Rizzo","year":"2021","journal-title":"Future Oncol"},{"key":"10.1016\/j.euf.2022.02.004_b0040","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2022.02.004_b0045","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2022.02.004_b0050","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2022.02.004_b0055","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2022.02.004_b0060","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2022.02.004_b0065","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2022.02.004_b0070","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ctrv.2013.09.003","article-title":"Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials","volume":"40","author":"Iacovelli","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.euf.2022.02.004_b0075","doi-asserted-by":"crossref","first-page":"33381","DOI":"10.18632\/oncotarget.8302","article-title":"Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma","volume":"7","author":"Santini","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.euf.2022.02.004_b0080","doi-asserted-by":"crossref","first-page":"102239","DOI":"10.1016\/j.ctrv.2021.102239","article-title":"Complete response and renal cell carcinoma in the immunotherapy era: the paradox of good news","volume":"99","author":"Zambrana","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.euf.2022.02.004_b0085","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1093\/annonc\/mdr533","article-title":"Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy","volume":"23","author":"Heng","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euf.2022.02.004_b0090","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3390\/cancers12010084","article-title":"Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: focus on sequences and prognostic factors","volume":"12","author":"Santoni","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euf.2022.02.004_b0095","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3390\/diagnostics11010138","article-title":"Body mass index in patients treated with cabozantinib for advanced renal cell carcinoma: a new prognostic factor?","volume":"11","author":"Santoni","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.euf.2022.02.004_b0100","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-update and clarification: from the RECIST Committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euf.2022.02.004_b0105","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2022.02.004_b0110","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s10555-013-9453-5","article-title":"Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside","volume":"33","author":"Santoni","year":"2014","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.euf.2022.02.004_b0115","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/CCO.0b013e32832a05c8","article-title":"Renal cell carcinoma","volume":"21","author":"Garcia","year":"2009","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.euf.2022.02.004_b0120","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.juro.2014.07.011","article-title":"Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma","volume":"193","author":"Santoni","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.euf.2022.02.004_b0125","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1586\/era.12.81","article-title":"Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science","volume":"12","author":"Porta","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.euf.2022.02.004_b0130","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00345-018-2264-0","article-title":"Pseudoprogression and hyper-progression during immune checkpoint inhibitor therapy for urothelial and kidney cancer","volume":"36","author":"Soria","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2022.02.004_b0135","article-title":"Long-term response to sunitinib treatment in metastatic renal cell carcinoma: a pooled analysis of clinical trials","author":"Tannir","year":"2022","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euf.2022.02.004_b0140","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.euf.2022.02.004_b0145","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s40425-018-0460-5","article-title":"Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance","volume":"6","author":"Boyiadzis","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euf.2022.02.004_b0150","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.eururo.2021.01.025","article-title":"Re: Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"79","author":"Santoni","year":"2021","journal-title":"Eur Urol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456922000499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456922000499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:53:53Z","timestamp":1762498433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456922000499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2405456922000499"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2022.02.004","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2022.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}